Rtw Biotech Regulatory News (RTW)

LEI: 549300Q7EXQQH6KF7Z84

1 October 2025

RTW Biotech Opportunities Ltd (the "Company")

Total Voting Rights

In accordance with DTR 5.6.1 of the FCA's Disclosure Guidance and Transparency Rules, the Company notifies the following:

As at the close of business on 30 September 2025, the Company had 345,967,440 Ordinary Shares in issue, of which 18,643,791 were held in treasury. Therefore, the total number of voting rights in the Company at that date was 327,323,649.

The above figure of 327,323,649 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.